AU2433400A - Use of 5-ht7 receptor antagonists for treating neuronal degeneration resulting from ischemic events - Google Patents

Use of 5-ht7 receptor antagonists for treating neuronal degeneration resulting from ischemic events

Info

Publication number
AU2433400A
AU2433400A AU24334/00A AU2433400A AU2433400A AU 2433400 A AU2433400 A AU 2433400A AU 24334/00 A AU24334/00 A AU 24334/00A AU 2433400 A AU2433400 A AU 2433400A AU 2433400 A AU2433400 A AU 2433400A
Authority
AU
Australia
Prior art keywords
receptor antagonists
neuronal degeneration
ischemic events
treating neuronal
degeneration resulting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24334/00A
Inventor
Peter Machin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2433400A publication Critical patent/AU2433400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU24334/00A 1998-12-18 1999-12-13 Use of 5-ht7 receptor antagonists for treating neuronal degeneration resulting from ischemic events Abandoned AU2433400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9828004 1998-12-18
GBGB9828004.3A GB9828004D0 (en) 1998-12-18 1998-12-18 Use
PCT/EP1999/010174 WO2000037082A1 (en) 1998-12-18 1999-12-13 Use of 5-ht7 receptor antagonists for treating neuronal degeneration resulting from ischemic events

Publications (1)

Publication Number Publication Date
AU2433400A true AU2433400A (en) 2000-07-12

Family

ID=10844566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24334/00A Abandoned AU2433400A (en) 1998-12-18 1999-12-13 Use of 5-ht7 receptor antagonists for treating neuronal degeneration resulting from ischemic events

Country Status (3)

Country Link
AU (1) AU2433400A (en)
GB (1) GB9828004D0 (en)
WO (1) WO2000037082A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683077B2 (en) 2003-05-20 2010-03-23 Ajinomoto Co., Inc. Piperidine derivative
ATE420881T1 (en) 2003-09-17 2009-01-15 Janssen Pharmaceutica Nv CONDENSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE SEROTONIN RECEPTOR
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20220023257A1 (en) * 2018-09-28 2022-01-27 Medizinische Hochschule Hannover (Mhh) Treatment of dementia-associated tauopathies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029097A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
JP2000512646A (en) * 1996-06-25 2000-09-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Sulfonamide derivatives as 5HT7 receptor antagonists
ATE296801T1 (en) * 1996-06-28 2005-06-15 Meiji Seika Kaisha TETRAHYDROBEZINDOLE DERIVATIVES
CN1129578C (en) * 1997-12-25 2003-12-03 明治制果株式会社 Tetrahydrobenzindole derivs
JP2002515408A (en) * 1998-05-19 2002-05-28 アルコン ラボラトリーズ， インコーポレーテッド Serotonergic 5HT7 receptor compounds for the treatment of ocular and central nervous system disorders

Also Published As

Publication number Publication date
GB9828004D0 (en) 1999-02-10
WO2000037082A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
IL133870A0 (en) Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
HUP0101627A3 (en) Pharmaceutical compositions for treating neuropsychiatric disorders
AU4060599A (en) Pharmaceutical composition for treating or preventing sleep disorders
AU2096895A (en) Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
AU7692996A (en) Receptor antagonists
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
AU4698299A (en) 5-HT7 receptor antagonists
AU3953795A (en) Bicyclic neuropeptide y receptor antagonists
IL138129A (en) Composition for therapy of estrogen-associated disorders
AU2242197A (en) Benzimidzolyl neuropeptide y receptor antagonists
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
AU4299397A (en) Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists
TW345297U (en) Adjusting secure seat for sound-wire of drum
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor
IL132520A0 (en) A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor
AU6569898A (en) Leukotriene antagonists useful for treating iritis
HUP0001459A3 (en) Process for the preparation of substituted thiazolidinedione derivatives
AU2433400A (en) Use of 5-ht7 receptor antagonists for treating neuronal degeneration resulting from ischemic events
HUP9800396A3 (en) Pharmaceutical composition for treating dementia
AU4768899A (en) Peptide antagonists of the human urokinase receptor and method for selecting them
AU1598499A (en) Methods for screening therapeutically effective agents
AU7059296A (en) NK-1 receptor antagonists for the treatment of cancer
GB2344586B (en) Isoquinuclidine derivatives,method of manufacturing the same and therapeutic agents for hypercholesterolemia containing these compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase